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ABSTRACT 
Objective: A simple, precise, and accurate stability indicating high-performance thin-layer chromatography (HPTLC) method was developed and 
validated for simultaneous estimation of linagliptin and metformin active pharmaceutical ingredients and fixed dose combination.  
Methods: Linagliptin and metformin densitograms were developed on silica gel 60 F254 HPTLC plates with acetone: methanol: chloroform: formic 
acid (3:1:5:1v/v) as the mobile phase. Densitometric quantification was performed at 230 nm.  
Results: For linagliptin and metformin RF values were found as 0.72 and 0.19, respectively. The method was validated for precision, accuracy, 
specificity, and robustness. The linearity curves were obtained in the concentration range of 100–600 ng per spot by area with correlation 
coefficients of 0.999 and 0.99 for linagliptin and metformin, respectively. Limit of detection was found to be 5.19 and 8.72 ng per spot for linagliptin 
and metformin, respectively; lowest possible quantity to be quantified by the proposed method was found to be 15.74 and 26.44 ng per spot for 
linagliptin and metformin, respectively. From stability studies, the noninterference of the linagliptin and metformin degradants with drugs 
demonstrated the suitability of the developed method.  
Conclusion: The developed method was validated and found to be selective, specific and suitable for application in pharmaceutical analysis of these 
drugs in bulk and fixed dose combination. 
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INTRODUCTION 
Diabetes treatment algorithm follows traditional stepwise approach 
involving lifestyle modifications, the addition of oral antidiabetic 
drugs (OAD). Where metformin stands out as the main drug for 
initial monotherapy, if initial monotherapy fails in achieving target 
glycemic controls over a period a combination therapy of multiple 
drugs is recommended. Drugs in the combination therapy have 
complimentary mechanisms by acting on different targets. These 
complimentary actions have drawn in focus to the usage of 
metformin (MET) along with a newer class of anti-diabetic drugs, 
i.e., dipeptidyl peptidase (DPP)-4 inhibitors [1].  
Linagliptin (LIN) is the major drug of choice to be used with 
metformin as a fixed dose combination for better glycemic control 
[2]. A survey of the literature revealed some HPLC and LC-MS/MS 
methods for analysis of MET alone and in combination with other 
drugs [3-9]. However, quite a few HPLC methods have been reported 
for simultaneous determination of MET with LIN in formulations 
[10, 11]. So far there is no reported HPTLC method for the 
simultaneous estimation of LIN and MET in the fixed dose 
combination. The present study was aimed to develop a simple, 
rapid and economical analytical method for the simultaneous 
estimation of linagliptin and metformin in bulk and fixed-dose 
combination for the routine analysis.  
MATERIALS AND METHODS  
Chemicals and reagents 
Linagliptin and metformin working standards were gift samples 
from MSN Pharma chem Pvt. Ltd. and Aurbindo Pharmaceuticals 
Ltd., respectively. Methanol, acetone, chloroform and formic acid of 
analytical grade were purchased from Sigma-Aldrich Inc. Precoated 
silica gel 60 F254 HPTLC plates (Merck # 5548) were purchased from 
E-Merck. Standard volumetric flasks were used for the preparation 
of all the dilutions. Millipore water and what man filter paper Grade 
I were used in the whole experimental work. 
Instrumentation and chromatographic conditions 
A 10 cm × 10 cm pre-coated silica gel 60 F254 (0.2 mm layer 
thickness) HPTLC plates were used for the development of 
chromatogram. CAMAG HPTLC system with Linomat V semi-
automatic applicator (CAMAG, Muttenz, Switzerland) equipped with 
CAMAG TLC scanner 3, operated through win CATS software 
(version 1.4.3) along with accessories like CAMAG twin trough 
chamber (20 cm x 20 cm), and CAMAG syringe of 100 μL capacity 
was used in the method development. The sample and standard 
solutions were applied on the plate as 8 mm width bands at an 
application rate of 150 nLs-1, with the flow of nitrogen gas (N2) for 
atomization of the solution.  
 
 
Fig. 1: Typical densitogram of metformin and linagliptin fixed 
dose combination 
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The spotted plates were developed to 80 mm distance in a CAMAG 
twin trough chamber pre-saturated for 10 min with mobile phase, i.e., 
acetone: methanol: chloroform: formic acid (3:1:5:1v/v). The 
chromatographic conditions were optimized for the best resolution 
and peak shape. Plates were dried after development and evaluated 
densitometrically at 230 nm with a CAMAG Scanner III, in combination 
with the win CATS software for quantitation. The method was 
validated according to the ICH guidelines [12, 13]. The typical 
chromatogram was shown in fig. 1. 
Preparation of working standard solution of linagliptin and 
metformin 
Accurately weighed 5 mg quantity of both the standard drugs were 
taken and transferred into a 10 ml clean, dry volumetric flask. The drugs 
were dissolved in methanol and made up to the final volume with 
methanol to obtain 500 µg/ml (stock solutions) of linagliptin and 
metformin. From these stock solutions, 2 ml was taken in 10 ml 
volumetric flask and volume was made up to the mark with methanol to 
obtain a concentration of 100 µg/ml of both the standard drugs. 
Preparation of sample solution 
Fixed dose working sample solutions were prepared by taking each 
5 mg of metformin and linagliptin into a single volumetric flask, and 
4 ml of methanol was added and sonicated for 25 min. Further 
volume was made up to 10 ml with methanol to obtain 500 µg/ml 
concentration solutions (stock solution). From this stock solution, 2 
ml was taken into a 10 ml volumetric flask and made up the volume 
to 10 ml with methanol. The resulting solution was used as a fixed 
dose combination of linagliptin and metformin containing 100 
µg/ml of each active component.  
RESULTS AND DISCUSSION 
Validation of proposed method 
The proposed method was validated for precision, accuracy, 
specificity, linearity and range, limit of detection (LOD), limit of 
quantitation (LOQ), and robustness. Validation of the proposed 
method was carried in accordance with the International Conference 
on Harmonization (ICH) guidelines [12, 13]. The current method is 
the first method so far for the simultaneous estimation of the 
linagliptin and metformin by HPTLC method.  
Linearity 
Aliquots of sample solutions were applied in the concentration range of 
100–600 ng per spot by applying 1-6 μL prepared standard solutions 
and chromatograms were developed under above optimized conditions. 
Linearity curves were shown in fig. 2A and 2B. The linearity range of the 
method was found more accurate and precise over the reported HPLC 
methods. The calibration curve was plotted as the concentration of the 
respective drug versus the mean of the response at each level. The 
proposed method was evaluated by its correlation coefficient and 
intercept value calculated in the statistical study and were represented 
by a linear regression equation. For linagliptin the linear regression 
equation was Y = 8.808X+130.478 and for metformin Y= 5.4X+95.201. 
The correlation coefficient of linagliptin and metformin was found to be 
0.999 for both the drugs. The observed RF values were 0.72 and 0.19 for 
linagliptin and metformin, respectively. 
Precision 
For linagliptin and metformin, the intra-day and inter-day precision 
studies were conducted under developed chromatographic conditions 
six times by using 200, 400 and 600 ng/spot concentrations. The 
method was found precise by exhibiting percentage estimation of 
about 100% and RSD less than 2% (table 1 & 2). 
 
Fig. 2: Linearity curves of (A) Linagliptin (B) Metformin 
 
Limit of detection and limit of quantitation 
The minimum amounts detected by the developed 
chromatographic conditions were estimated in terms of the LOD. 
By area, LOD was found to be 5.19 and 8.72 ng per spot for 
linagliptin and metformin, respectively. Lowest possible quantity 
to be quantified by the proposed method was found to be 15.74 
and 26.44 ng per spot for linagliptin and metformin, 
respectively. The present method derived superior method with 
lower LOD and LOQ values than the method reported by 
Rajasekaran et al. [14]. The lower level of LOD and LOQ indicates 
the applicability of the developed method to a wide range of 
concentrations than the reported HPLC methods [10, 11].  
Accuracy 
The accuracy of the developed method was established by standard 
addition method by adding known standard concentration solutions to 
the pre-analyzed samples in different levels, i.e., 50, 100 and 150 %. 
The samples were analyzed for five times at each level. The mean 
recovery and RSD values were calculated. Recoveries of linagliptin 
(table 3) and metformin (table 4) were in between 98-102 %. This is 
in accordance with ICH guidelines. Therefore method was found to 
be accurate. 
  
Table 1: Precision study of proposed stability-indicating HPTLC method for linagliptin 
Conc. (ng/spot) Intraday precision (n = 6) Intermediate precision (n = 6) 
 mean±SD % RSD mean±SD % RSD 
200 1883.593±14.04 0.74 1824.22±12.91 0.70 
400 3610.016±24.29 0.67 3609.09±22.94 0.63 
600 4940.55±5.64 0.11 4939.02±14.58  0.29 
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Table 2: Precision study of proposed stability-indicating HPTLC method for metformin 
Conc. (ng/spot) Intraday precision (n = 6) Intermediate precision (n = 6) 
 mean±SD % RSD Mean.±SD % RSD 
200 1031.51±6.69 0.64 1078.71±16.05 1.48 
400 2050.21±33.33 1.62 2154.65±25.38 1.17 
600 3304.23±34.81 1.08 3244.28±27.01 0.83 
 
Table 3: Linagliptin accuracy of method in terms of % recovery (n = 5) 
Spiked amount (ng/spot) Amount detected±SD Mean % recovered % RSD  
200 (50%) 599.68±2.73 99.94  0.45 
400 (100%) 801.14±4.04 100.13  0.50 
600 (150%) 1004.41±5.39 100.44  0.53 
 
Table 4: Metformin accuracy of method in terms of % recovery (n = 5) 
Spiked amount (ng/spot) Amount detected±SD Mean % recovered % RSD  
200 (50%) 600.87±2.53 100.13 0.40 
400 (100%) 802.31±2.32 100.33 0.28 
600 (150%) 1008.25±10.80 100.82 1.07 
 
Specificity (Stability studies)  
The stability studies of the analytes were conducted for the 
developed method to evaluate how accurately and specifically 
the analyte of interest is estimated in the presence of other 
components (e. g. degradation products, excipients etc.) by 
subjecting the sample to various stress conditions such as acidic 
(0.1 N HCl, 1N HCl), alkaline (0.1 N NaOH, 1N NaOH), oxidizing 
(3% H2O2) for 1 hour and photolytic degradation for 24 h, 
followed by analysis of them by proposed method. From the 
studies, it was found that the LIN was relatively stable than MET 
under acidic, basic, peroxide and photolytic degradation 
conditions (table 5, Fig.3.).  
The proposed method was demonstrated its specificity for the 
analyzed drugs, where analyte peaks was not affected by the 
degradants. This proves that the method was suitable and selective 
for the routine analysis. 
 
 
Fig. 3: Densitograms of linagliptin and metformin combination under stress induced degradation conditions 
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Table 5: Stress-induced degradation studies (n = 3) 
Stress conditions Time (h) Mean % recovered±SD 
Linagliptin Metformin 
HCl (0.1 N) 1 95.43±2.72 84.56±1.85  
HCl (1.0 N) 1 76.18±1.86 48.74±2.68 
NaOH (0.1 N) 1 82.23±2.33 52.93±1.81 
NaOH (1.0 N) 1 64.82±1.43 23.29±0.63 
H2O2 (3% v/v) 1 55.99±1.85  36.15±0.83 
Day light 24 91.08±2.37  42.73±1.29 
 
Robustness 
The robustness of an analytical method evaluates the method 
capacity to remain unaffected by minor but purposeful variations in 
the method parameters and provides an indication of its reliability 
during normal usage. Robustness of the developed method was 
evaluated by the analysis of sample solutions after making small 
changes in the mobile phase volume and mobile phase saturation 
time. The low value of % RSD shows that the method is robust and 
that a slight change in mobile phase volume and mobile phase 
saturation time does not affect the results.  
CONCLUSION 
The developed method was simple, precise, and accurate for the 
determination of LIN and MET and their degradation product in bulk 
drug and pharmaceutical preparations. The method was validated for 
precision, accuracy, specificity, and robustness. Therefore, the method 
can be applied for routine quality control analysis of LIN, and MET in 
active pharmaceutical ingredients and in fixed-dose combinations.  
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